Švédsko - švédčina - Läkemedelsverket (Medical Products Agency)

mimer medical - atorvastatinkalciumtrihydrat - filmdragerad tablett - 40 mg - atorvastatinkalciumtrihydrat 43,38 mg aktiv substans; laktosmonohydrat hjälpämne - atorvastatin

Švédsko - švédčina - Läkemedelsverket (Medical Products Agency)

ranbaxy (uk) ltd - atorvastatinkalcium, amorft - filmdragerad tablett - 10 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; atorvastatinkalcium, amorft 10,3 mg aktiv substans; butylhydroxianisol hjälpämne; sackaros hjälpämne; bronopol hjälpämne - atorvastatin

Švédsko - švédčina - Läkemedelsverket (Medical Products Agency)

ranbaxy (uk) ltd - atorvastatinkalcium, amorft - filmdragerad tablett - 20 mg - atorvastatinkalcium, amorft 20,7 mg aktiv substans; bronopol hjälpämne; sackaros hjälpämne; natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; butylhydroxianisol hjälpämne - atorvastatin

Švédsko - švédčina - Läkemedelsverket (Medical Products Agency)

ranbaxy (uk) ltd - atorvastatinkalcium, amorft - filmdragerad tablett - 40 mg - bronopol hjälpämne; sackaros hjälpämne; atorvastatinkalcium, amorft 41,4 mg aktiv substans; butylhydroxianisol hjälpämne; laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne - atorvastatin

Švédsko - švédčina - Läkemedelsverket (Medical Products Agency)

ranbaxy (uk) ltd - atorvastatinkalcium, amorft - filmdragerad tablett - 80 mg - atorvastatinkalcium, amorft 82,7 mg aktiv substans; butylhydroxianisol hjälpämne; laktosmonohydrat hjälpämne; sackaros hjälpämne; bronopol hjälpämne; natriumlaurilsulfat hjälpämne - atorvastatin

Európska únia - švédčina - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrit, reumatoid - immunsuppressiva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Európska únia - švédčina - EMA (European Medicines Agency)

virbac s.a. - hydrokortisonacceponat - kortikosteroider, dermatologiska preparat - hundar - för symptomatisk behandling av inflammatoriska och pruritiska dermatoser hos hundar. for alleviation of clinical signs associated with atopic dermatitis in dogs.

Európska únia - švédčina - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artrit, reumatoid - immunsuppressiva - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant kan användas som monoterapi eller i kombination med metotrexat. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Švédsko - švédčina - Läkemedelsverket (Medical Products Agency)

ab atoma - cineol; kajeputolja; levomentol; pepparmyntolja - inhalationsånga, lösning - pepparmyntolja 200 mg aktiv substans; kajeputolja 200 mg aktiv substans; levomentol 400 mg aktiv substans; cineol 200 mg aktiv substans - avsvällande och övriga medel för lokal behandling vid nässjukdomar

Švédsko - švédčina - Läkemedelsverket (Medical Products Agency)

ab atoma - eukalyptusolja; kajeputolja; pepparmyntolja - inhalationsånga, salva - jordnötsolja, hydrogenerad hjälpämne; kajeputolja 15 mg aktiv substans; cetostearylalkohol hjälpämne; cetylalkohol hjälpämne; pepparmyntolja 65,25 mg aktiv substans; propylenglykol hjälpämne; eukalyptusolja 60 mg aktiv substans - Övriga medel mot förkylning